Cyproheptadine inhibits in vitro and in vivo lung metastasis and drives metabolic rewiring

• DOI: 10.1007/s11033-024-10033-6
• Publication Date: 2024-11-10T08:00:09Z
• Authors: Ahmad Shannar; Md Shahid Sarwar; Parv Dushyant Dave; PoChung Jordan Chou; Rebecca Mary Peter; Jiawei Xu; Yuxin Pan; Fabio Rossi; Ah-Ng Kong
• Keywords: Cyproheptadine

Non-small cell lung cancer (NSCLC) accounts for 81% of cases, among which over 47% presented with distant metastasis at the time diagnosis. Despite introduction targeted therapy and immunotherapy, enhancing survival rate overcoming development resistance remain a big challenge. Thus, it is crucial to find potential new therapeutics targets that can mitigate investigate its effects on biomarkers, such as cellular metabolomics. In current study, we investigated role cyproheptadine (CPH), an FDA-approved anti-histamine drug in vitro vivo.